Today at the ISSCR 2026 Annual Meeting, Jeanne Loring, Ph.D., Scripps Research, USA, will present interim clinical findings from the first Phase 1/2a trial using autologous induced pluripotent stem cell (iPSC)-derived dopamine neuron precursor cells, along with the novel quality control tools developed to manufacture these individualized therapies.

Parkinson's disease is a progressive neurological disorder caused by the gradual loss of dopamine-producing nerve cells in the brain. As dopamine levels decline, people develop symptoms such as tremor, stiffness, slowed movement, and balance problems. While current medications can temporarily improve symptoms, they do not stop the disease from progressing or replace the neurons that have been lost.

Previously unpublished long-term clinical and imaging findings from participants treated with an induced pluripotent stem cell (iPSC)-derived neural progenitor cell therapy for chronic ischemic stroke were presented today at the ISSCR 2026 Annual Meeting.

The data include extended follow-up from Phase I studies evaluating hNPC01, an iPSC-derived forebrain neural progenitor cell therapy designed to promote repair of stroke-damaged brain tissue. The findings provide new insight into the long-term safety, feasibility, and biological activity of this regenerative approach in patients living with chronic motor disability following stroke.

The International Society for Stem Cell Research (ISSCR) today opened its 2026 Annual Meeting in Montréal, bringing together thousands of scientists, clinicians, industry leaders, regulators, trainees, and patient advocates from around the world for four days of scientific discovery, collaboration, and innovation across the stem cell field.

‍Co-sponsored by STEMCELL Technologies, ISSCR 2026 showcases the full spectrum of stem cell research from fundamental discoveries in developmental biology to emerging clinical advances, disease modeling, regenerative medicine, gene editing, and new technologies that are shaping the future of biomedical science.

Encellin today announced new clinical progress from its ongoing Phase 1 study evaluating its implantable cell therapy platform for people with type 1 diabetes. The company made the announcement in connection with the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, reporting non-fibrotic engraftment across all seven participants enrolled in the trial, along with host vascularization at the implant site and identification of transplanted islets in multiple participants. The findings build upon interim results first reported in January 2026 and reflect a larger patient cohort, with analysis of the full clinical dataset ongoing.